Finance

Lists
Why is FAE down 2,24%?
Dive Deeper
FAE:BME
FAES Farma SA
4,80 €
-2,24%
(-0,11) 1D
13-окт., 17:36:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for FAE...
Open
4,92 €
High
4,94 €
Low
4,76 €
Mkt. cap
1,59 млд
Avg. vol.
194,90 миң
Volume
163,97 миң
Dividend
2,67%
Quarterly dividend
0,03 €
Ex-dividend date
2026-ж., 2-июл.
P/E ratio
17,85
52-wk high
5,44 €
52-wk low
4,32 €
EPS
0,27 €
Shares outstanding
316,22 млн
No. of employees
3 миң
Open
4,92 €
High
4,94 €
Low
4,76 €
Mkt. cap
1,59 млд
Avg. vol.
194,90 миң
Volume
163,97 миң
Dividend
2,67%
Quarterly dividend
0,03 €
Ex-dividend date
2026-ж., 2-июл.
P/E ratio
17,85
52-wk high
5,44 €
52-wk low
4,32 €
EPS
0,27 €
Shares outstanding
316,22 млн
No. of employees
3 миң
News stories
From web sources and news partners
Profile
Faes Farma, originally Fábrica Española de Productos Químicos y Farmacéuticos, is a Spanish pharmaceutical company based in the Lamiaco district of Lejona in Biscay. Founded on 29 July 1933 by the Serra family with an initial capital of two million pesetas, it pioneered the development of various therapeutic compounds and has been listed on the Madrid Stock Exchange since the 1940s. Faes Farma’s headquarters, production facilities, and R&D center are located in Lejona, with additional offices in Madrid and Barcelona. The group also operates subsidiaries in Portugal, Italy, Mexico, Guatemala, Colombia, Chile, Peru, Bolivia, Ecuador and Nigeria, and maintains an animal nutrition and health division under the name FARM Faes. Wikipedia
About FAES Farma SA
CEO-
Employees2,61 миң
Founded1933-ж., 29-июл.
Headquarters-
SectorPharmaceutical industry
Last report
2026-ж., 30-июл.
Fiscal period
Q2 2026
0,09 € / -
0,00%miss
Revenue / Est. (EUR)
401,85 млн / 189,65 млн
+111,89%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
146,61 млн
172,99 млн
200,07 млн
191,39 млн
Cost of goods sold
52,40 млн
73,44 млн
61,59 млн
60,25 млн
Cost of revenue
52,40 млн
73,44 млн
61,59 млн
60,25 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27,36 млн
80,84 млн
45,67 млн
44,06 млн
Operating expense
68,06 млн
98,44 млн
100,13 млн
98,54 млн
Total operating expenses
120,47 млн
171,88 млн
161,72 млн
158,78 млн
Operating income
26,14 млн
1,11 млн
38,35 млн
32,61 млн
Other non operating income
401,00 миң
1,02 млн
-
-
EBT including unusual items
25,18 млн
-1,39 млн
36,36 млн
30,47 млн
EBT excluding unusual items
25,18 млн
-1,65 млн
36,36 млн
30,47 млн
Income tax expense
3,75 млн
-7,43 млн
5,49 млн
4,32 млн
Effective tax rate
14,91%
534,46%
15,10%
14,19%
Other operating expenses
33,65 млн
7,21 млн
44,62 млн
44,44 млн
Net income
21,23 млн
6,07 млн
30,79 млн
26,10 млн
Net profit margin
14,48%
3,51%
15,39%
13,64%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
1,41 млн
Interest expense
-1,99 млн
-3,51 млн
-1,99 млн
-3,58 млн
Net interest expenses
-1,99 млн
-3,51 млн
-1,99 млн
-2,18 млн
Depreciation and amortization charges
7,05 млн
10,39 млн
9,83 млн
10,04 млн
EBITDA
30,15 млн
6,94 млн
44,19 млн
40,50 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору